Results 71 to 80 of about 18,995 (290)

Sex‐Specific Regulation of Glycemic Homeostasis by Theabrownin from Pu‐erh Tea

open access: yesAdvanced Science, EarlyView.
Pu‐erh tea's key component, theabrownin (TB), lowers blood glucose in a sex‐specific manner. In females, estrogen boosts intestinal MUC2 production, which dramatically enhances TB's ability to inhibit the carbohydrate‐digesting enzyme α‐glucosidase.
Yang Li   +22 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Enhancing therapeutic efficacy in luminal androgen receptor triple-negative breast cancer: exploring chidamide and enzalutamide as a promising combination strategy

open access: yesCancer Cell International
Extensive exploration of the molecular subtypes of triple-negative breast cancer (TNBC) is critical for advancing precision medicine. Notably, the luminal androgen receptor (LAR) subtype has attracted attention for targeted treatment combining androgen ...
Ya-Xin Zhao   +5 more
doaj   +1 more source

Inhibition of androgen receptor by decoy molecules delays progression to castration-recurrent prostate cancer. [PDF]

open access: yesPLoS ONE, 2017
Androgen receptor (AR) is a member of the steroid receptor family and a therapeutic target for all stages of prostate cancer. AR is activated by ligand binding within its C-terminus ligand-binding domain (LBD).
Jae-Kyung Myung   +5 more
doaj   +1 more source

Androgen Receptor‐Induced Lactoferrin Accelerates Prostate Tumorigenesis Through Modulating Ferroptosis

open access: yesAdvanced Science, EarlyView.
This study demonstrates that transcription factor androgen receptor (AR) directly binds the LF promoter, driving lactoferrin overexpression to promote ferritin (FTH1/FTL) upregulation and inhibit p53‐ALOX12‐mediated ferroptosis in prostate cancer. Lactoferrin could be a new potential therapeutic target in prostate cancer.
Can Liu   +18 more
wiley   +1 more source

Design and Synthesis of 4‑(4-Benzoylaminophenoxy)phenol Derivatives As Androgen Receptor Antagonists

open access: yes, 2016
We report the design and synthesis of novel 4-(4-benzoylaminophenoxy)­phenol derivatives that bind to the androgen receptor (AR) ligand-binding domain and exhibit potent androgen-antagonistic activity.
Shuichi Mori (362273)   +3 more
core   +2 more sources

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

open access: yesAdvanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu   +7 more
wiley   +1 more source

Insights from the Structure of Estrogen Receptor into the Evolution of Estrogens: Implications for Endocrine Disruption

open access: yes, 2011
In the last decade, there has been important progress in understanding the origins and evolution of receptors for adrenal steroids (aldosterone, cortisol) and sex steroids (estradiol, progesterone, testosterone) due to the sequencing of genomes from ...
Michael E. Baker
core   +1 more source

Bicalutamide Functions as an Androgen Receptor Antagonist by Assembly of a Transcriptionally Inactive Receptor [PDF]

open access: yesJournal of Biological Chemistry, 2002
Prostate cancers (PCa) that relapse after androgen deprivation therapy invariably express high levels of androgen receptor (AR) and AR-regulated genes. Most do not respond to secondary hormonal therapies, including AR antagonists, and the mechanisms of AR activation in these clinically androgen-independent tumors are unclear.
David, Masiello   +4 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy